iRhythm’s Zio XT cardiac monitor [Image from iRhythm]
San Francisco-based iRhythm’s KP-Rhythm2 study — published in the American Journal of Cardiology — examined the efficiency of Zio XT, Holter monitors and event monitors with the aim of assessing diagnostic yield, outcomes and resource utilization by monitoring modality in individuals without previously documented atrial fibrillation (AFib) or atrial flutter (AFL).
According to a news release, while earlier studies have proven Zio XT to be better than Holter and event monitors for detecting arrhythmias, the KP-Rhythm2 study (led by Kaiser Permanente and supported by a research grant from iRhythm) is the first to specifically address the Zio XT patch against a 30-day event monitor yielding similar diagnostic yield for AFib and AFL in a general population of adults without known prior AFib/AFL.
Zio XT was associated with significantly higher documentation of AFib/AFL-related supraventricular tachycardia and non-sustained ventricular tachycardia compared to both 24-hour Holter and 30-day event monitoring, iRhythm said.
“It’s been demonstrated that Holter monitors often result in repeat testing, longer time to diagnosis, increased costs of healthcare, and a delay to clinical intervention,” iRhythm CEO Quentin Blackford said in the new release. “This latest clinical research further validates that monitoring with Zio by iRhythm leads to better diagnostic yield and aids in more accurate diagnoses.”
iRhythm also touted the results of the Brady-TAVR study aimed at determining the prevalence of bradyarrhythmias among patients undergoing transcatheter aortic valve replacement (TAVR) and whether pre- and post-TAVR extended rhythm monitoring with Zio XT would aid in the prediction of conduction disturbances and permanent pacemaker (PPM) implantation risk.
The study found that bradyarrhythmias can be detected with 14-day cardiac monitoring through the Zio XT platform both before and after TAVR, iRhythm said.
